Competitive Acquisition Program (CAP): You would be able to obtain low-cost, high-volume drugs under the CAP rule, although potential vendors don't like that idea

Why This Topic Matters

The piece helps readers understand how CMS’s drug acquisition model could affect access, vendor participation, and practice operations for frequently billed Part B drugs. It is useful for organizations tracking federal Medicare policy changes affecting drug supply, billing workflows, and vendor relationships.

Article Sections

1. Program overview and vendor concerns

   Introduces the proposed competitive acquisition program and summarizes the main concerns raised by potential vendors about participation and distribution of Part B drugs.

2. Implementation timing and vendor participation

   Covers CMS’s stated timeline for the interim final rule and the expected structure for vendor selection and national service coverage.

3. Unanswered questions remain

   Reviews open operational issues discussed during the teleconference, including drug volume handling, wastage, and distribution access concerns.

4. Frequently billed, low-cost drugs

   Presents a table of commonly billed low-cost drugs with utilization and pricing information referenced in the article.